Innovative drugs refer to compounds that have not been marketed at home or abroad, contain new compounds with clear structures and have pharmacological effects, and have both clinical value and independent intellectual property rights
.
In recent years, under the accelerated development and reform of the pharmaceutical industry, innovative drugs have become the key word in China's pharmaceutical industry.
A large number of new drug R&D companies such as 3SBio, Hengrui, Chia Tai Tianqing, and Zejing Pharmaceutical have emerged in the market.
R&D investment continued to grow
.
Today, through the unremitting efforts of these domestic innovative drug companies, some innovative results are emerging, bringing new growth points for pharmaceutical companies and bred new market opportunities
.
Innovative drugs have become a new growth point for a large number of pharmaceutical companies, giving birth to new market opportunities! (Image source: Pharmaceutical Network)
Hansoh Pharma: Innovative drugs account for more than half of revenue
Hansoh Pharma: Innovative drugs account for more than half of revenue
On August 26, the semi-annual performance report released by Hansoh Pharmaceuticals showed that the company achieved revenue of about 4.
434 billion yuan in the first half of the year, of which the revenue of innovative drugs was about 2.
321 billion yuan, a year-on-year increase of about 84.
8%, and the proportion of innovative drugs in revenue increased from 2021.
About 28.
5% in the same period rose to about 52.
3%, a new high
.
Hansoh Pharma has a rich pipeline of research and development.
Up to now, the company has conducted more than 40 clinical trials of innovative drugs, involving more than 25 innovative drug projects in different clinical stages, covering anti-tumor, central nervous system, anti-infection, metabolism, and autoimmunity.
5 major indication areas
.
In the first half of 2022, there are 3 self-developed projects and 1 BD project newly entered into clinical projects
.
In addition, Hansoh Pharma has also deployed diversified international frontier new drug technology fields such as siRNA, ADC and fusion proteins
.
And there are a number of product research projects in steady progress
.
China Biopharma: Innovation and Transformation Drive Performance Growth
China Biopharma: Innovation and Transformation Drive Performance Growth
On August 23, Sino Biopharmaceuticals released its 2022 semi-annual performance report.
In the first half of this year, the company achieved double growth in revenue and competitiveness, of which innovation and transformation had an obvious effect on performance
.
Data show that in the first half of this year, China's biopharmaceutical research and development investment was 2.
19 billion yuan, of which the research and development investment of innovative drugs and biological drugs accounted for more than 73.
7%, and the investment amount increased by 51.
4% year-on-year
.
With high R&D investment, new products, innovative drugs, and oncology drugs have also become the second growth curve of China's biopharmaceutical revenue, of which innovative drug revenue totaled 3.
49 billion yuan, accounting for 22.
9% of revenue, a year-on-year increase of 14.
2%
.
The semi-annual report also disclosed that the company's innovative drug revenue will account for 24% of the company's innovative drug revenue this year, and the innovative drug revenue is expected to exceed the 10 billion yuan mark in 2023
.
Huadong Medicine: Pinning on the Successful R&D of Innovative Drugs
Huadong Medicine: Pinning on the Successful R&D of Innovative Drugs
In addition, Huadong Medicine, the 130.
25% growth of its medical beauty business in the first half of the year, also pinned its hopes on the successful research and development of innovative drugs
.
In the first half of this year, the company's research and development expenses were 567 million yuan, a year-on-year increase of 29.
45%
.
As of the first half of this year, Huadong Medicine has 43 innovative drugs and biosimilars in reserve or under development
.
Among them, the fast progress is the liraglutide injection for the treatment of obesity and diabetes.
The drug has submitted and accepted the application for marketing authorization and is expected to be approved this year
.
Up to now, only Novo Nordisk sells liraglutide injection on the market in China, with sales of about 1.
5 billion yuan in 2021, with an average annual compound growth rate of about 30%
.
According to industry estimates, the market size of this product is expected to reach 2.
5 billion yuan in 2024
.
In addition to Huadong Medicine, Tonghua Dongbao, Hanyu Pharmaceutical, and a number of pharmaceutical companies such as Fosun Pharmaceutical are in the research and development stage
.
Epilogue
Epilogue
Innovation is a major trend in the development of the pharmaceutical industry.
The industry believes that the innovation system is complete, the harvest period is approaching, and enterprises related to the innovation industry chain are expected to benefit
.
According to data from Frost & Sullivan, the global innovative drug market has reached a scale of nearly one trillion US dollars
.
As medical improvement enters the deep water area, differentiated innovation will become the main theme of the development of pharmaceutical companies in the future
.
Domestic innovative drug companies are expected to continue to accelerate the pace of innovation in the future, and harvest more innovation achievements, which is worth looking forward to
.
